Dashboard
Manage Tickers

LLY ELI LILLY & Co

NYSE lilly.com


$ 1,016.01 $ 22.94 (2.31 %)    

Wednesday, 12-Nov-2025 09:55:01 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 620.08 $ -4.70 (-0.75 %)
DIA $ 483.67 $ 3.11 (0.65 %)
SPY $ 683.39 $ -1.41 (-0.21 %)
TLT $ 90.04 $ 0.09 (0.1 %)
GLD $ 380.71 $ 0.60 (0.16 %)
$ 988.62
$ 992.57
$ 1,015.50 x 102
$ 1,017.35 x 14
$ 990.14 - $ 1,019.88
$ 622.41 - $ 999.95
4,166,380
na
888.57B
$ 0.53
$ 48.26
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 04-29-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 10-27-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 04-30-2021 03-31-2021 10-Q
20 02-17-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-19-2020 12-31-2019 10-K
25 10-25-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-27-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 10-27-2017 09-30-2017 10-Q
34 07-28-2017 06-30-2017 10-Q
35 05-01-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-28-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-29-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

100-invested-in-eli-lilly-10-years-ago-would-be-worth-this-much-today
$100 Invested In Eli Lilly 10 Years Ago Wo...
11/12/2025 14:30:51

eli-lilly-drops-cvs-healths-drug-benefit-plan-for-employees-ahead-of-2026-switch
Eli Lilly Drops CVS Health's Drug Benefit ...
11/12/2025 13:42:59

Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India t...

eli-lilly-ceo-slams-pbm-rent-taking-says-they-drove-insulin-list-prices-to-275-we-can-disintermediate-them-easily
Eli Lilly CEO Slams PBM 'Rent Taking', Say...
11/12/2025 11:22:15

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready ...

Core News & Articles
'Lilly Drops CVS Drug Plan for Workers Aft...
11/12/2025 07:43:56

https://www.bloomberg.com/news/articles/2025-11-12/lilly-drops-cvs-drug-plan-for-workers-after-novo-obesity-deal 

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
11/11/2025 17:35:21

these-20-stocks-now-make-up-half-of-the-sp-500heres-why-thats-risky
These 20 Stocks Now Make Up Half Of The S&...
11/11/2025 15:29:21

A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...

trifecta-health-partners-with-eli-lillys-lillydirect-to-expand-affordable-access-to-zepbound-obesity-treatment
Trifecta Health Partners With Eli Lilly's ...
11/11/2025 13:59:54

Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to hi...

freedom-capital-markets-downgrades-eli-lilly-to-hold-raises-price-target-to-950
Freedom Capital Markets Downgrades Eli Lil...
11/10/2025 21:05:07

Freedom Capital Markets analyst Ilya Zubkov downgrades Eli Lilly (NYSE:LLY) from Buy to Hold and raises the price target fro...

heres-how-much-100-invested-in-eli-lilly-15-years-ago-would-be-worth-today
Here's How Much $100 Invested In Eli Lilly...
11/10/2025 20:45:32

eli-lilly-stock-surges-as-analyst-sees-more-room-to-run
Eli Lilly Stock Surges As Analyst Sees Mor...
11/10/2025 19:06:51

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.

markets-cheer-as-shutdown-end-nears-these-15-stocks-are-rallying
Markets Cheer As Shutdown End Nears: These...
11/10/2025 15:33:18

Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown i...

eli-lilly-expands-genetic-eye-disease-focused-pipeline-with-meiragtx-gene-therapy-collaboration
Eli Lilly Expands Genetic Eye-Disease Focu...
11/10/2025 14:11:55

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children w...

this-hasbro-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday
This Hasbro Analyst Begins Coverage On A B...
11/10/2025 13:45:01

zscaler-to-rally-more-than-9-here-are-10-top-analyst-forecasts-for-monday
Zscaler To Rally More Than 9%? Here Are 10...
11/10/2025 13:37:49

Core News & Articles
MeiraGTx Holdings Announced A Broad Strate...
11/10/2025 12:12:07

12-analysts-have-this-to-say-about-eli-lilly
12 Analysts Have This To Say About Eli Lilly
11/10/2025 11:45:13

this-eli-lilly-analyst-turns-bullish-here-are-top-5-upgrades-for-monday
This Eli Lilly Analyst Turns Bullish; Here...
11/10/2025 11:35:52

leerink-partners-upgrades-eli-lilly-to-outperform-raises-price-target-to-1104
Leerink Partners Upgrades Eli Lilly to Out...
11/10/2025 11:31:22

Leerink Partners analyst David Risinger upgrades Eli Lilly (NYSE:LLY) from Market Perform to Outperform and raises the price...

pfizer-clinches-10-billion-deal-to-buy-obesity-drug-maker-metsera-outbidding-novo-nordisk-in-fierce-battle-for-weight-loss-market-dominance
Pfizer Clinches $10 Billion Deal To Buy Ob...
11/08/2025 06:56:08

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...

eli-lillys-investigational-obesity-drug-shows-up-to-20-weight-loss-in-phase-2-study-analyst-sees-it-as-emerging-cornerstone-in-obesity-treatment
Eli Lilly's Investigational Obesity Drug S...
11/07/2025 17:33:23

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION